FDA approves Jazz's Vyxeos for AML

FDA approved Vyxeos (CPX-351) from Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to treat adults with 2 types of acute myelogenous leukemia (AML) -- newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC).

On Aug. 3, Jazz said it expects to launch Vyxeos within a week. The drug's label includes a boxed warning not to interchange Vyxeos with other daunorubicin and/or cytarabine-containing products...